Insider Selling: NantHealth Inc (NH) COO Sells 6,175 Shares of Stock

NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 6,175 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $3.52, for a total value of $21,736.00. Following the transaction, the chief operating officer now directly owns 89,690 shares in the company, valued at $315,708.80. The sale was disclosed in a filing with the SEC, which is available through this link.

Ronald Allen Louks also recently made the following trade(s):

  • On Wednesday, December 6th, Ronald Allen Louks sold 5,245 shares of NantHealth stock. The shares were sold at an average price of $3.03, for a total value of $15,892.35.
  • On Monday, November 6th, Ronald Allen Louks sold 6,705 shares of NantHealth stock. The shares were sold at an average price of $3.39, for a total value of $22,729.95.

NantHealth Inc (NH) traded up $0.01 during trading on Friday, reaching $3.76. The company’s stock had a trading volume of 131,900 shares, compared to its average volume of 191,137. NantHealth Inc has a twelve month low of $2.60 and a twelve month high of $10.19. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93. The stock has a market cap of $407.32 and a P/E ratio of -2.58.

NantHealth (NASDAQ:NH) last issued its earnings results on Thursday, November 9th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The firm had revenue of $21.76 million for the quarter, compared to the consensus estimate of $29.42 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. analysts expect that NantHealth Inc will post -1.35 EPS for the current fiscal year.

NH has been the topic of several research analyst reports. Zacks Investment Research downgraded NantHealth from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. BidaskClub downgraded NantHealth from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. Canaccord Genuity dropped their price target on NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. Finally, Jefferies Group reiterated a “buy” rating and set a $5.00 price target on shares of NantHealth in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $8.05.

Institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of NantHealth by 91.5% in the second quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after buying an additional 81,024 shares during the last quarter. GSA Capital Partners LLP boosted its position in NantHealth by 154.7% during the third quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock worth $299,000 after purchasing an additional 44,100 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in NantHealth by 136.9% during the second quarter. TIAA CREF Investment Management LLC now owns 47,848 shares of the company’s stock worth $202,000 after purchasing an additional 27,648 shares in the last quarter. National Planning Corp boosted its position in NantHealth by 21.1% during the third quarter. National Planning Corp now owns 138,700 shares of the company’s stock worth $656,000 after purchasing an additional 24,200 shares in the last quarter. Finally, Highbridge Capital Management LLC boosted its position in NantHealth by 6.5% during the third quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock worth $1,030,000 after purchasing an additional 15,264 shares in the last quarter. Hedge funds and other institutional investors own 7.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: NantHealth Inc (NH) COO Sells 6,175 Shares of Stock” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/12/insider-selling-nanthealth-inc-nh-coo-sells-6175-shares-of-stock.html.

NantHealth Company Profile

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply